NIH Honcho: ‘Impossible’ To Predict COVID Vaccine By November

WASHINGTON, DC - JULY 2: Dr. Francis Collins, Director of the National Institutes of Health (NIH), testifies during a US Senate Appropriations subcommittee hearing on the plan to research, manufacture and distribute ... WASHINGTON, DC - JULY 2: Dr. Francis Collins, Director of the National Institutes of Health (NIH), testifies during a US Senate Appropriations subcommittee hearing on the plan to research, manufacture and distribute a coronavirus vaccine, known as Operation Warp Speed, July 2, 2020 on Capitol Hill in Washington, DC. (Photo by Saul Loeb-Pool/Getty Images) MORE LESS

It’s impossible to know if there will be a safe and effective vaccine by November, National Institutes of Health Director Francis Collins told the Senate on Wednesday morning.

“Will it be done by a certain date? I could not possibly tell you right now,” Dr. Collins told Sen. Bernie Sanders (D-VT) during a hearing of the Senate health committee. “Certainly, to try to predict whether it happens on a particular week before or after a particular date in early November is well beyond anything that any scientist right now could tell you and know what they’re saying.”

Collins added that “science and science alone will lead the way. Otherwise, I’ll have no part of it.”

As head of NIH, Collins does not play a direct role in approving an eventual COVID-19 vaccine.

Rather, that task falls to the Food and Drug Administration, which is overseeing three COVID-19 vaccines that are currently in mass, phase III trials.

President Trump has been pressuring the FDA to approve a vaccine before the November election in a bid to juice his re-election chances. Some of the President’s advisors have reportedly referred to a pre-election vaccine as a “holy grail” for President Trump’s re-election prospects.

Several states have told TPM that they would refuse to distribute a vaccine that did not complete phase III trials or which did not pass muster under review from an independent board of scientists.

Collins added, “I don’t know what is going to happen.”

“I do have cautious optimism that by the end of 2020, one of these vaccines will have emerged and turned out to be safe and effective,” he added.

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

Latest Muckraker
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriters:
Director of Audience:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: